Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-07

AUTHORS

George Dranitsaris, Lesley G Shane, Jean-Philippe Galanaud, Gunar Stemer, Philippe Debourdeau, Seth Woodruff

ABSTRACT

BACKGROUND: International guidelines recommend extended duration secondary prophylaxis in cancer patients who develop primary venous thromboembolism (VTE). Agent selection is guided in part by one large randomized trial (i.e., CLOT; Lee et al., N Engl J Med 349:146-53, 2003) which demonstrated that dalteparin reduced the relative risk of recurrence by 52% compared with oral vitamin K antagonists (VKA; HR = 0.48, 95% CI, 0.30 to 0.77). In a subgroup analysis from that same trial, patients with renal impairment also derived benefit with dalteparin (VTE rates = 3% vs. 17%; p = 0.011). To measure the economic value of secondary VTE prophylaxis with dalteparin, a patient-level pharmacoeconomic analysis was conducted from the Austrian and French healthcare system perspectives. METHODS: Chapter 1 Healthcare resource use collected during the CLOT trial was extracted and converted into direct cost estimates. Incremental cost differences between the dalteparin and VKA groups were then combined with health state utilities to measure the cost per quality-adjusted life year (QALY) gained. RESULTS: The dalteparin group had significantly higher costs than the VKA group in both countries (Austria: dalteparin = €2687 vs. VKA = €2012; France: dalteparin = €2053 vs. VKA = €1352: p < 0.001). However, when the incremental costs were combined with the utility gain, dalteparin had a cost of €6600 and €4900 per QALY gained in Austria and France, respectively. The analyses in patients with renal impairment suggested an even better economic profile, with the cost per QALY gained being less than €4000 in both countries. CONCLUSIONS: Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer. More... »

PAGES

2093-2102

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2

DOI

http://dx.doi.org/10.1007/s00520-017-3610-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1083842709

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28204995


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Austria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dalteparin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "France", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Venous Thromboembolism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vitamin K", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Augmentium Pharma Consulting (Canada)", 
          "id": "https://www.grid.ac/institutes/grid.459408.4", 
          "name": [
            "Augmentium Pharma Consulting Inc, 283 Danforth Ave, Suite 448 M4K 1N2, Toronto, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dranitsaris", 
        "givenName": "George", 
        "id": "sg:person.01036510774.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036510774.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shane", 
        "givenName": "Lesley G", 
        "id": "sg:person.0712705253.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712705253.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital of Montpellier", 
          "id": "https://www.grid.ac/institutes/grid.157868.5", 
          "name": [
            "Montpellier University Hospital, Montpellier, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Galanaud", 
        "givenName": "Jean-Philippe", 
        "id": "sg:person.01232632524.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232632524.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vienna General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411904.9", 
          "name": [
            "Vienna General Hospital, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stemer", 
        "givenName": "Gunar", 
        "id": "sg:person.01075516054.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075516054.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Sainte Catherine", 
          "id": "https://www.grid.ac/institutes/grid.482015.a", 
          "name": [
            "Institut Sainte Catherine, Avignon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Debourdeau", 
        "givenName": "Philippe", 
        "id": "sg:person.01224577007.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224577007.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Woodruff", 
        "givenName": "Seth", 
        "id": "sg:person.015700301775.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015700301775.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40258-014-0130-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000246041", 
          "https://doi.org/10.1007/s40258-014-0130-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1538-7836.2006.01804.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004624260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1538-7836.2006.01804.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004624260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.thromres.2014.11.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012980372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11239-016-1386-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014677169", 
          "https://doi.org/10.1007/s11239-016-1386-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11239-016-1386-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014677169", 
          "https://doi.org/10.1007/s11239-016-1386-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ceor.s39964", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015048941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015902157", 
          "https://doi.org/10.1038/sj.bjc.6605417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015902157", 
          "https://doi.org/10.1038/sj.bjc.6605417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03256152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016443579", 
          "https://doi.org/10.1007/bf03256152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020566522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70232-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020618217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.49.1118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022692210"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa025313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024707641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-006-0062-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024921848", 
          "https://doi.org/10.1007/s00520-006-0062-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-006-0062-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024921848", 
          "https://doi.org/10.1007/s00520-006-0062-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01262566", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025411356", 
          "https://doi.org/10.1007/bf01262566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01262566", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025411356", 
          "https://doi.org/10.1007/bf01262566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0021-9681(87)90019-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029030291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2015.9243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032108796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4103/0973-1482.39685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032170623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000022400", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034488207"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1538-7836.2003.00396.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038182500"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00129784-200404050-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038658520", 
          "https://doi.org/10.2165/00129784-200404050-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00129784-200404050-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038658520", 
          "https://doi.org/10.2165/00129784-200404050-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.11-2296", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039499818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ceor.s85635", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041106407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr392", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048198947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-015-0187-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049493237", 
          "https://doi.org/10.1007/s12325-015-0187-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.22.3271", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050418707"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ceor.s126379", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052050478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.27772", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053084726"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.suponc.2010.09.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054750578"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2165/11314740-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077966207"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-07", 
    "datePublishedReg": "2017-07-01", 
    "description": "BACKGROUND: International guidelines recommend extended duration secondary prophylaxis in cancer patients who develop primary venous thromboembolism (VTE). Agent selection is guided in part by one large randomized trial (i.e., CLOT; Lee et al., N Engl J Med 349:146-53, 2003) which demonstrated that dalteparin reduced the relative risk of recurrence by 52% compared with oral vitamin K antagonists (VKA; HR\u00a0=\u00a00.48, 95% CI, 0.30 to 0.77). In a subgroup analysis from that same trial, patients with renal impairment also derived benefit with dalteparin (VTE rates\u00a0=\u00a03% vs. 17%; p\u00a0=\u00a00.011). To measure the economic value of secondary VTE prophylaxis with dalteparin, a patient-level pharmacoeconomic analysis was conducted from the Austrian and French healthcare system perspectives.\nMETHODS: Chapter 1 Healthcare resource use collected during the CLOT trial was extracted and converted into direct cost estimates. Incremental cost differences between the dalteparin and VKA groups were then combined with health state utilities to measure the cost per quality-adjusted life year (QALY) gained.\nRESULTS: The dalteparin group had significantly higher costs than the VKA group in both countries (Austria: dalteparin\u00a0=\u00a0\u20ac2687 vs. VKA\u00a0=\u00a0\u20ac2012; France: dalteparin\u00a0=\u00a0\u20ac2053 vs. VKA\u00a0=\u00a0\u20ac1352: p\u00a0<\u00a00.001). However, when the incremental costs were combined with the utility gain, dalteparin had a cost of \u20ac6600 and \u20ac4900 per QALY gained in Austria and France, respectively. The analyses in patients with renal impairment suggested an even better economic profile, with the cost per QALY gained being less than \u20ac4000 in both countries.\nCONCLUSIONS: Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00520-017-3610-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1103473", 
        "issn": [
          "0941-4355", 
          "1433-7339"
        ], 
        "name": "Supportive Care in Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "name": "Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria", 
    "pagination": "2093-2102", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "13f1a0cf82b5631a4296b157428aa018d512317fe95cf14003b8d7df2a3d685f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28204995"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9302957"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00520-017-3610-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1083842709"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00520-017-3610-2", 
      "https://app.dimensions.ai/details/publication/pub.1083842709"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99824_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00520-017-3610-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00520-017-3610-2'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      71 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00520-017-3610-2 schema:about N0703931894274c20a4920d421ce8947f
2 N080104cd7edd4a4190ee0f4f068c4ff7
3 N11f8e54cba104176b9abe95db469bb87
4 N15b2bb19f6c14bd5a1c8e528f7d112e5
5 N322a61f92dbd4709ac5fd7ee7fcb8e20
6 N3f7b38fc221f4726854f261309b692cc
7 N4616ef40d66f48a184f9e4d31f4f1420
8 N60c1ace184394bf8ac79c9c911310817
9 Naed197a82fbe40b1b41c2545ca31cbe4
10 Nb398146382db4418aea0b0447153d0c3
11 Ncb4dd43f93894637a9df88b335b0e8f7
12 Nde1426be55584eeabe1822b6702f4682
13 Ne42b4192cbc94381a15f3939710b8024
14 Nf00f1a80a12a4033b38f3d8242235da7
15 anzsrc-for:11
16 anzsrc-for:1117
17 schema:author N530d31eb2f7d4472b32eb3f0dd53cf2b
18 schema:citation sg:pub.10.1007/bf01262566
19 sg:pub.10.1007/bf03256152
20 sg:pub.10.1007/s00520-006-0062-5
21 sg:pub.10.1007/s11239-016-1386-8
22 sg:pub.10.1007/s12325-015-0187-3
23 sg:pub.10.1007/s40258-014-0130-9
24 sg:pub.10.1038/sj.bjc.6605417
25 sg:pub.10.2165/00129784-200404050-00005
26 https://doi.org/10.1001/jama.2015.9243
27 https://doi.org/10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o
28 https://doi.org/10.1002/cncr.27772
29 https://doi.org/10.1016/0021-9681(87)90019-1
30 https://doi.org/10.1016/j.suponc.2010.09.027
31 https://doi.org/10.1016/j.thromres.2014.11.024
32 https://doi.org/10.1016/s1470-2045(09)70232-3
33 https://doi.org/10.1046/j.1538-7836.2003.00396.x
34 https://doi.org/10.1056/nejmoa025313
35 https://doi.org/10.1093/annonc/mdr392
36 https://doi.org/10.1111/j.1538-7836.2006.01804.x
37 https://doi.org/10.1159/000022400
38 https://doi.org/10.1200/jco.2009.22.3271
39 https://doi.org/10.1200/jco.2013.49.1118
40 https://doi.org/10.1378/chest.11-2296
41 https://doi.org/10.2147/ceor.s126379
42 https://doi.org/10.2147/ceor.s39964
43 https://doi.org/10.2147/ceor.s85635
44 https://doi.org/10.2165/11314740-000000000-00000
45 https://doi.org/10.4103/0973-1482.39685
46 schema:datePublished 2017-07
47 schema:datePublishedReg 2017-07-01
48 schema:description BACKGROUND: International guidelines recommend extended duration secondary prophylaxis in cancer patients who develop primary venous thromboembolism (VTE). Agent selection is guided in part by one large randomized trial (i.e., CLOT; Lee et al., N Engl J Med 349:146-53, 2003) which demonstrated that dalteparin reduced the relative risk of recurrence by 52% compared with oral vitamin K antagonists (VKA; HR = 0.48, 95% CI, 0.30 to 0.77). In a subgroup analysis from that same trial, patients with renal impairment also derived benefit with dalteparin (VTE rates = 3% vs. 17%; p = 0.011). To measure the economic value of secondary VTE prophylaxis with dalteparin, a patient-level pharmacoeconomic analysis was conducted from the Austrian and French healthcare system perspectives. METHODS: Chapter 1 Healthcare resource use collected during the CLOT trial was extracted and converted into direct cost estimates. Incremental cost differences between the dalteparin and VKA groups were then combined with health state utilities to measure the cost per quality-adjusted life year (QALY) gained. RESULTS: The dalteparin group had significantly higher costs than the VKA group in both countries (Austria: dalteparin = €2687 vs. VKA = €2012; France: dalteparin = €2053 vs. VKA = €1352: p < 0.001). However, when the incremental costs were combined with the utility gain, dalteparin had a cost of €6600 and €4900 per QALY gained in Austria and France, respectively. The analyses in patients with renal impairment suggested an even better economic profile, with the cost per QALY gained being less than €4000 in both countries. CONCLUSIONS: Secondary prophylaxis with dalteparin is a cost-effective alternative to VKA for the prevention of recurrent VTE in patients with cancer.
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree false
52 schema:isPartOf N645eeaf256a54c92951d67685276c1ae
53 N680b48092fff41358f2bda61a78e731d
54 sg:journal.1103473
55 schema:name Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria
56 schema:pagination 2093-2102
57 schema:productId N42a1d472a15d4f4da7d406656747caff
58 N450580000c744f8b921bf2cb8b2e42b7
59 N4cc02d6746054fbbba6e734a2e26a46f
60 N7312482748034a39848e0ece089747be
61 N7e0b1f313b6f4c1fa957a8eb2c8bdab1
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083842709
63 https://doi.org/10.1007/s00520-017-3610-2
64 schema:sdDatePublished 2019-04-11T09:36
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N7bf045d3801b4d0fa0a4d4695604a727
67 schema:url https://link.springer.com/10.1007%2Fs00520-017-3610-2
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N0703931894274c20a4920d421ce8947f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Humans
73 rdf:type schema:DefinedTerm
74 N07533687f12b49ea8c3ea5dc3140e95a rdf:first sg:person.015700301775.03
75 rdf:rest rdf:nil
76 N080104cd7edd4a4190ee0f4f068c4ff7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Male
78 rdf:type schema:DefinedTerm
79 N094061d0b7784d6d90424008a7d3cdac rdf:first sg:person.01224577007.14
80 rdf:rest N07533687f12b49ea8c3ea5dc3140e95a
81 N11f8e54cba104176b9abe95db469bb87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Female
83 rdf:type schema:DefinedTerm
84 N14fe6aff56a64dedb2b3b922171aa20c rdf:first sg:person.01075516054.30
85 rdf:rest N094061d0b7784d6d90424008a7d3cdac
86 N15b2bb19f6c14bd5a1c8e528f7d112e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Neoplasms
88 rdf:type schema:DefinedTerm
89 N322a61f92dbd4709ac5fd7ee7fcb8e20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Anticoagulants
91 rdf:type schema:DefinedTerm
92 N3f7b38fc221f4726854f261309b692cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Cost-Benefit Analysis
94 rdf:type schema:DefinedTerm
95 N42a1d472a15d4f4da7d406656747caff schema:name readcube_id
96 schema:value 13f1a0cf82b5631a4296b157428aa018d512317fe95cf14003b8d7df2a3d685f
97 rdf:type schema:PropertyValue
98 N450580000c744f8b921bf2cb8b2e42b7 schema:name pubmed_id
99 schema:value 28204995
100 rdf:type schema:PropertyValue
101 N4616ef40d66f48a184f9e4d31f4f1420 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Quality of Life
103 rdf:type schema:DefinedTerm
104 N4cc02d6746054fbbba6e734a2e26a46f schema:name dimensions_id
105 schema:value pub.1083842709
106 rdf:type schema:PropertyValue
107 N530d31eb2f7d4472b32eb3f0dd53cf2b rdf:first sg:person.01036510774.09
108 rdf:rest N81c5416a9a8946c1bb7e2ca6493a04b3
109 N60c1ace184394bf8ac79c9c911310817 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Recurrence
111 rdf:type schema:DefinedTerm
112 N645eeaf256a54c92951d67685276c1ae schema:volumeNumber 25
113 rdf:type schema:PublicationVolume
114 N680b48092fff41358f2bda61a78e731d schema:issueNumber 7
115 rdf:type schema:PublicationIssue
116 N7312482748034a39848e0ece089747be schema:name doi
117 schema:value 10.1007/s00520-017-3610-2
118 rdf:type schema:PropertyValue
119 N7bf045d3801b4d0fa0a4d4695604a727 schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 N7e0b1f313b6f4c1fa957a8eb2c8bdab1 schema:name nlm_unique_id
122 schema:value 9302957
123 rdf:type schema:PropertyValue
124 N81c5416a9a8946c1bb7e2ca6493a04b3 rdf:first sg:person.0712705253.03
125 rdf:rest Nc4d9042e4c9c47cbb8a2d73b0ca58606
126 Naed197a82fbe40b1b41c2545ca31cbe4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Middle Aged
128 rdf:type schema:DefinedTerm
129 Nb398146382db4418aea0b0447153d0c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Dalteparin
131 rdf:type schema:DefinedTerm
132 Nc4d9042e4c9c47cbb8a2d73b0ca58606 rdf:first sg:person.01232632524.54
133 rdf:rest N14fe6aff56a64dedb2b3b922171aa20c
134 Ncb4dd43f93894637a9df88b335b0e8f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name France
136 rdf:type schema:DefinedTerm
137 Nde1426be55584eeabe1822b6702f4682 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Venous Thromboembolism
139 rdf:type schema:DefinedTerm
140 Ne42b4192cbc94381a15f3939710b8024 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Vitamin K
142 rdf:type schema:DefinedTerm
143 Nf00f1a80a12a4033b38f3d8242235da7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Austria
145 rdf:type schema:DefinedTerm
146 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
147 schema:name Medical and Health Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
150 schema:name Public Health and Health Services
151 rdf:type schema:DefinedTerm
152 sg:journal.1103473 schema:issn 0941-4355
153 1433-7339
154 schema:name Supportive Care in Cancer
155 rdf:type schema:Periodical
156 sg:person.01036510774.09 schema:affiliation https://www.grid.ac/institutes/grid.459408.4
157 schema:familyName Dranitsaris
158 schema:givenName George
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036510774.09
160 rdf:type schema:Person
161 sg:person.01075516054.30 schema:affiliation https://www.grid.ac/institutes/grid.411904.9
162 schema:familyName Stemer
163 schema:givenName Gunar
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075516054.30
165 rdf:type schema:Person
166 sg:person.01224577007.14 schema:affiliation https://www.grid.ac/institutes/grid.482015.a
167 schema:familyName Debourdeau
168 schema:givenName Philippe
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224577007.14
170 rdf:type schema:Person
171 sg:person.01232632524.54 schema:affiliation https://www.grid.ac/institutes/grid.157868.5
172 schema:familyName Galanaud
173 schema:givenName Jean-Philippe
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232632524.54
175 rdf:type schema:Person
176 sg:person.015700301775.03 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
177 schema:familyName Woodruff
178 schema:givenName Seth
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015700301775.03
180 rdf:type schema:Person
181 sg:person.0712705253.03 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
182 schema:familyName Shane
183 schema:givenName Lesley G
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712705253.03
185 rdf:type schema:Person
186 sg:pub.10.1007/bf01262566 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025411356
187 https://doi.org/10.1007/bf01262566
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/bf03256152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016443579
190 https://doi.org/10.1007/bf03256152
191 rdf:type schema:CreativeWork
192 sg:pub.10.1007/s00520-006-0062-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024921848
193 https://doi.org/10.1007/s00520-006-0062-5
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/s11239-016-1386-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014677169
196 https://doi.org/10.1007/s11239-016-1386-8
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/s12325-015-0187-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049493237
199 https://doi.org/10.1007/s12325-015-0187-3
200 rdf:type schema:CreativeWork
201 sg:pub.10.1007/s40258-014-0130-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000246041
202 https://doi.org/10.1007/s40258-014-0130-9
203 rdf:type schema:CreativeWork
204 sg:pub.10.1038/sj.bjc.6605417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015902157
205 https://doi.org/10.1038/sj.bjc.6605417
206 rdf:type schema:CreativeWork
207 sg:pub.10.2165/00129784-200404050-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038658520
208 https://doi.org/10.2165/00129784-200404050-00005
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1001/jama.2015.9243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032108796
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1002/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1020566522
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1002/cncr.27772 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053084726
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/0021-9681(87)90019-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029030291
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/j.suponc.2010.09.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054750578
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/j.thromres.2014.11.024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012980372
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s1470-2045(09)70232-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020618217
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1046/j.1538-7836.2003.00396.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038182500
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1056/nejmoa025313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024707641
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1093/annonc/mdr392 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048198947
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1111/j.1538-7836.2006.01804.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004624260
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1159/000022400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034488207
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1200/jco.2009.22.3271 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050418707
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.2013.49.1118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022692210
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1378/chest.11-2296 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039499818
239 rdf:type schema:CreativeWork
240 https://doi.org/10.2147/ceor.s126379 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052050478
241 rdf:type schema:CreativeWork
242 https://doi.org/10.2147/ceor.s39964 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015048941
243 rdf:type schema:CreativeWork
244 https://doi.org/10.2147/ceor.s85635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041106407
245 rdf:type schema:CreativeWork
246 https://doi.org/10.2165/11314740-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077966207
247 rdf:type schema:CreativeWork
248 https://doi.org/10.4103/0973-1482.39685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032170623
249 rdf:type schema:CreativeWork
250 https://www.grid.ac/institutes/grid.157868.5 schema:alternateName University Hospital of Montpellier
251 schema:name Montpellier University Hospital, Montpellier, France
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
254 schema:name Pfizer Inc, New York, NY, USA
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.411904.9 schema:alternateName Vienna General Hospital
257 schema:name Vienna General Hospital, Vienna, Austria
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.459408.4 schema:alternateName Augmentium Pharma Consulting (Canada)
260 schema:name Augmentium Pharma Consulting Inc, 283 Danforth Ave, Suite 448 M4K 1N2, Toronto, Canada
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.482015.a schema:alternateName Institut Sainte Catherine
263 schema:name Institut Sainte Catherine, Avignon, France
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...